Beam complexity and monitor unit efficiency comparison in two different volumetric modulated arc therapy delivery systems using automated planning

Background To investigate the beam complexity and monitor unit (MU) efficiency issues for two different volumetric modulated arc therapy (VMAT) delivery technologies for patients with left-sided breast cancer (BC) and nasopharyngeal carcinoma (NPC). Methods Twelve left-sided BC and seven NPC cases were enrolled in this study. Each delivered treatment plan was optimized in the Pinnacle(3) treatment planning system with the Auto-Planning module for the Trilogy and Synergy systems. Similar planning dose objectives and beam configurations were used for each site in the two different delivery systems to produce clinically acceptable plans. The beam complexity was evaluated in terms of the segment area (SA), segment width (SW), leaf sequence variability (LSV), aperture area variability (AAV), and modulation complexity score (MCS) based on the multileaf collimator sequence and MU. Plan delivery and a gamma evaluation were performed using a helical diode array. Results With similar plan quality, the average SAs for the Trilogy plans were smaller than those for the Synergy plans: 55.5 +/- 21.3 cm(2) vs. 66.3 +/- 17.9 cm(2) (p < 0.05) for the NPC cases and 100.7 +/- 49.2 cm(2) vs. 108.5 +/- 42.7 cm(2) (p < 0.05) for the BC cases, respectively. The SW was statistically significant for the two delivery systems (NPC: 6.87 +/- 1.95 cm vs. 6.72 +/- 2.71 cm, p < 0.05; BC: 8.84 +/- 2.56 cm vs. 8.09 +/- 2.63 cm, p < 0.05). The LSV was significantly smaller for Trilogy (NPC: 0.84 +/- 0.033 vs. 0.86 +/- 0.033, p < 0.05; BC: 0.89 +/- 0.026 vs. 0.90 +/- 0.26, p < 0.05). The mean AAV was significantly larger for Trilogy than for Synergy (NPC: 0.18 +/- 0.064 vs. 0.14 +/- 0.037, p < 0.05; BC: 0.46 +/- 0.15 vs. 0.33 +/- 0.13, p < 0.05). The MCS values for Trilogy were higher than those for Synergy: 0.14 +/- 0.016 vs. 0.12 +/- 0.017 (p < 0.05) for the NPC cases and 0.42 +/- 0.106 vs. 0.30 +/- 0.087 (p < 0.05) for the BC cases. Compared with the Synergy plans, the average MUs for the Trilogy plans were larger: 828.6 +/- 74.1 MU and 782.9 +/- 85.2 MU (p > 0.05) for the NPC cases and 444.8 +/- 61.3 MU and 393.8 +/- 75.3 MU (p > 0.05) for the BC cases. The gamma index agreement scores were never below 91% using 3 mm/3% (global) distance to agreement and dose difference criteria and a 10% lower dose exclusion threshold. Conclusions The Pinnacle(3) Auto-Planning system can optimize BC and NPC plans to achieve the same plan quality using both the Trilogy and Synergy systems. We found that